Nonoperating Income (Expense) in USD of Checkpoint Therapeutics, Inc. from Q4 2014 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Checkpoint Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and change rate from Q4 2014 to Q1 2025.
  • Checkpoint Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending 31 Mar 2025 was -$63K, a 2200% decline year-over-year.
  • Checkpoint Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending 31 Mar 2025 was -$132K, a 98.2% increase year-over-year.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was -$66K, a 122% decline from 2023.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $301K.
  • Checkpoint Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.29M, a 8196% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Checkpoint Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$132K -$63K -$66K -2200% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$66K -$71K +$8.89M +99.2% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025
Q3 2024 -$8.95M -$1K -$1.98M -100% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 -$6.98M $3K +$329K 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024
Q1 2024 -$7.31M $3K -$7.61M -100% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025
Q4 2023 $301K -$8.96M -$4.58M -105% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025
Q3 2023 $4.88M $1.98M +$1.93M +3702% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $2.96M -$326K -$348K -1582% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024
Q1 2023 $3.31M $7.61M +$7.6M +58431% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024
Q4 2022 -$4.29M -$4.38M -$4.39M -31371% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024
Q3 2022 $101K $52K +$39K +300% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023
Q2 2022 $62K $22K +$9K +69.2% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $53K $13K $0 0% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 $53K $14K -$3K -17.6% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 $56K $13K -$1K -7.14% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $57K $13K -$16K -55.2% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022
Q1 2021 $73K $13K -$47K -78.3% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 $120K $17K -$14K -45.2% 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022
Q3 2020 $134K $14K -$14K -50% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $148K $29K -$6K -17.1% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021
Q1 2020 $154K $60K +$18K +42.9% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021
Q4 2019 $136K $31K -$242K -88.6% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021
Q3 2019 $378K $28K -$15K -34.9% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020
Q2 2019 $393K $35K -$4K -10.3% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 $397K $42K +$24K +133% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 $373K $273K +$252K +1200% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020
Q3 2018 $121K $43K +$21K +95.5% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $100K $39K +$15K +62.5% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 $85K $18K -$13K -41.9% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 $98K $21K +$9K +75% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019
Q3 2017 $89K $22K +$11K +100% 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2018
Q2 2017 $78K $24K +$11K +84.6% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 $67K $31K +$364K 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$297K $12K +$613K 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 -$910K $11K +$81K 01 Jul 2016 30 Sep 2016 10-K 16 Mar 2018
Q2 2016 -$991K $13K +$13K 01 Apr 2016 30 Jun 2016 10-K 16 Mar 2018
Q1 2016 -$1M -$333K -$333K 01 Jan 2016 31 Mar 2016 10-K 16 Mar 2018
Q4 2015 -$671K -$601K -$601K 01 Oct 2015 31 Dec 2015 10-K 21 Mar 2017
Q3 2015 -$70K -$70K 01 Jul 2015 30 Sep 2015 10-K 21 Mar 2017
Q2 2015 $0 01 Apr 2015 30 Jun 2015 10-K 21 Mar 2017
Q1 2015 $0 01 Jan 2015 31 Mar 2015 10-K 21 Mar 2017
Q4 2014 $0 10 Nov 2014 31 Dec 2014 10-K 21 Mar 2017

Checkpoint Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$66K -$367K -122% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025
2023 $301K +$4.59M 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025
2022 -$4.29M -$4.34M -8196% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024
2021 $53K -$67K -55.8% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 $120K -$16K -11.8% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022
2019 $136K -$237K -63.5% 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021
2018 $373K +$275K +281% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020
2017 $98K +$395K 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019
2016 -$297K +$374K +55.7% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018
2015 -$671K 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.